Adv Ther (2017) 34:2612–2624 DOI 10.1007/s12325-017-0643-3 ORIGINAL RESEARCH The Inﬂuence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies . . . Tomohiro Kusawake Donna Kowalski Akitsugu Takada . . . . Kota Kato Masataka Katashima James J. Keirns Michaelene Lewand . . Kenneth C. Lasseter Thomas C. Marbury Richard A. Preston Received: September 25, 2017 / Published online: November 13, 2017 The Author(s) 2017. This article is an open access publication hepatic impairment and mild, moderate, and ABSTRACT severe renal impairment. Results: In the hepatic impairment study, the Introduction: Amenamevir (ASP2151) is a pharmacokinetic proﬁle of amenamevir in par- nonnucleoside human herpesvirus helicase-pri- ticipants with moderate hepatic impairment mase inhibitor that was approved in Japan for was generally similar to that of participants the treatment of herpes zoster (shingles) in with normal hepatic function. In the renal 2017. This article reports the results of two impairment study, the area under the ame- clinical trials that investigated the effects of namevir concentration versus time curve from renal and hepatic impairment on the pharma- the time of dosing up to the time of the last cokinetics of
Advances in Therapy – Springer Journals
Published: Nov 13, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera